Product Images Felodipine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 4 images provide visual information about the product associated with Felodipine NDC 72162-1743 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
image description - 1 formula
Label - lbl721621743
table 1 - table 1
table 2 - table 2
Percent of Patients with Adverse Events in Controlled Trials of Felodipine Extended-Release Tablets: - Body System: - Peripheral Edema: 33 (0) patients on placebo, 2 (0) patients on 25mg, 88 (22) patients on 5mg, and 174 (25) patients on 10mg experienced this adverse event. - Asthenia: 33 (0) patients on placebo, 39 (0) patients on 25mg, 0.33 (0) patients on 5mg, and 22 (0) patients on 10mg experienced this adverse event. - Warm Sensation: 0 (0) patients on placebo, 0 (0) patients on 25mg, 9 (2) patients on 5mg, and 15 (0) patients on 10mg experienced this adverse event. - Cardiovascular: - Palpitation: 24 (0) patients on placebo, 4 (0) patients on 25mg, 14 (3) patients on 5mg, and 25 (5) patients on 10mg experienced this adverse event. - Digestive: - Nausea: 15 (9) patients on placebo, 12 (0) patients on 25mg, 17 (3) patients on 5mg, and 1 (7) patients on 10mg experienced this adverse event. - Dyspepsia: 12 (0) patients on placebo, 39 (0) patients on 25mg, 7 (0) patients on 5mg, and 5 (0) patients on 10mg experienced this adverse event. - Constipation: 9 (0) patients on placebo, 12 (0) patients on 25mg, 3 (0) patients on 5mg, and 15 (0.2) patients on 10mg experienced this adverse event. - Nervous: - Headache: 102 (9) patients on placebo, 106 (4) patients on 25mg, 11 (17) patients on 5mg, and 147 (2) patients on 10mg experienced this adverse event. - Dizziness: 27 (3) patients on placebo, 27 (0) patients on 25mg, 36 (5) patients on 5mg, and 37 (5) patients on 10mg experienced this adverse event. - Paresthesia: 15 (3) patients on placebo, 16 (0) patients on 25mg, 12 (0) patients on 5mg, and 12002 patients on 10mg experienced this adverse event. - Respiratory: - Upper Respiratory Infection: 1.8 (0) patients on placebo, 39 (0) patients on 25mg, 19 (0) patients on 5mg, and 7 (0) patients on 10mg experienced this adverse event. - Cough: 0.3 (0) patients on placebo, 8 (0) patients on 25mg, 12 (0) patients on 5mg, and 17 (0) patients on 10mg experienced this adverse event. - Rhinorthea: 0 (0) patients on placebo, 16 (0) patients on 25mg, 2 (0) patients on 5mg, and 2 (0) patients on 10mg experienced this adverse event. - Sneezing: 0 (0) patients on placebo, 16 (0) patients on 25mg, 0 (0) patients on 5mg, and 0 (0) patients on 10mg experienced this adverse event. - Skin: - Rash: 0 (0) patients on placebo, 2 (0) patients on 25mg, 2 (0) patients on 5mg, and 2 (0) patients on 10mg experienced this adverse event. - Flushing: 0.9 (0.3) patients on placebo, 39 (0) patients on 25mg, 53 (7) patients on 5mg, and 69 (1.2) patients on 10mg experienced this adverse event. Please note that the data includes patients on different doses of felodipine extended-release tablets and the discontinuations were shown in parentheses.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
